Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Ascierto PA, et al. Among authors: anderson ac. J Immunother Cancer. 2020 Apr;8(1):e000878. doi: 10.1136/jitc-2020-000878. J Immunother Cancer. 2020. PMID: 32300051 Free PMC article. No abstract available.
Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N, Sabatos-Peyton C, Anderson AC. Acharya N, et al. Among authors: anderson ac. J Immunother Cancer. 2020 Jun;8(1):e000911. doi: 10.1136/jitc-2020-000911. J Immunother Cancer. 2020. PMID: 32601081 Free PMC article. Review.
Consensus nomenclature for CD8+ T cell phenotypes in cancer.
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Apetoh L, et al. Among authors: anderson ac. Oncoimmunology. 2015 Feb 25;4(4):e998538. doi: 10.1080/2162402X.2014.998538. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137416 Free PMC article.
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu HJ, Ophir M, Lambden C, Bakhru P, Gilmore DC, Ottinger S, Liu L, McConaughy WK, He SQ, Wang C, Leung CL, Lajoie J, Carson WF 4th, Zizlsperger N, Schmidt MM, Anderson AC, Bobrowicz P, Schuetz TJ, Tighe R. Eskiocak U, et al. Among authors: anderson ac. JCI Insight. 2020 Mar 12;5(5):e133647. doi: 10.1172/jci.insight.133647. JCI Insight. 2020. PMID: 32161196 Free PMC article.
Introduction to the Special Issue: Immuno-oncology.
Anderson AC, Kuchroo VK. Anderson AC, et al. Semin Immunol. 2021 Feb;52:101483. doi: 10.1016/j.smim.2021.101483. Epub 2021 Jul 1. Semin Immunol. 2021. PMID: 34219003 No abstract available.
371 results